文献速递慢阻肺

干细胞治疗慢阻肺:希望与商业剥削

Stem Cell Therapy for COPD: Hope and Exploitation.
PubMed 文献 · Chest · 2021-04-21

慢阻肺是进行性肺功能下降的慢性炎症和破坏性疾病,临床前研究提示间充质干细胞(MSCs)因抗炎、修复和免疫调节特性可能成为治疗选择。现有临床试验显示MSCs在慢阻肺患者中安全,但缺乏大型多中心随机试验,无证据支持其能恢复肺功能。细胞干预的研究性状态未能阻止商业推广和医疗旅游,导致未经证实且可能有害的干预泛滥。

要点

  • MSCs在慢阻肺临床试验中显示安全,但缺乏疗效证据。
  • 无大型多中心随机试验支持MSCs恢复肺功能。
  • 商业推广和医疗旅游利用未证实细胞干预,患者面临风险。

核心结论

  • MSCs在慢阻肺患者中安全,但无证据支持其恢复肺功能。
  • 细胞干预的研究性状态未阻止商业剥削和医疗旅游推广。

研究设计与样本

  • 综述,总结临床前研究和临床试验证据。

主要发现

  • 临床前研究提示MSCs具有抗炎、修复和免疫调节特性。
  • 临床试验显示MSCs在慢阻肺患者中安全。
  • 缺乏大型多中心随机试验,无疗效证据。
  • 商业企业和医疗旅游推广未经证实的细胞干预。

临床怎么用

  • 应告知患者MSCs治疗慢阻肺缺乏疗效证据,警惕商业推广。

局限性

  • 缺乏大型多中心随机试验,无法评估疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COPD is a chronic inflammatory and destructive disease characterized by progressive decline in lung function that can accelerate with aging. Preclinical studies suggest that mesenchymal stem cells (MSCs) may provide a therapeutic option for this incurable disease because of their antiinflammatory, reparative, and immunomodulatory properties. To date, clinical trials using MSCs demonstrate safety in patients with COPD. However, because of the notable absence of large, multicenter randomized trials, no efficacy or evidence exists to support the possibility that MSCs can restore lung function in patients with COPD. Unfortunately, the investigational status of cell-based interventions for lung diseases has not hindered the propagation of commercial businesses, exploitation of the public, and explosion of medical tourism to promote unproven and potentially harmful cell-based interventions for COPD in the United States and worldwide. Patients with COPD constitute the largest group of patients with lung disease flocking to these unregulated clinics. This review highlights the numerous questions and concerns that remain before the establishment of cell-based interventions as safe and efficacious treatments for patients with COPD.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Glassberg MK, Csete I, Simonet E, et al. Stem Cell Therapy for COPD: Hope and Exploitation. Chest. 2021. PMID: 33894254. doi:10.1016/j.chest.2021.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。